Cosciens Biopharma (CSCI) investor relations material

Executive summary

• Undertook a comprehensive restructuring plan in 2025 to streamline operations and enhance efficiency, resulting in a significantly reduced burn rate and right-sized organization.

• Ceased funding German subsidiaries in March 2026, leading to insolvency proceedings and expected $1.9 million in annualized cost savings.

• Focused on further administrative cost reductions, including plans to suspend U.S. public reporting obligations while maintaining Canadian reporting and listings.

• Committed to pursuing additional cost savings, achieving profitability, and exploring both organic growth and strategic transactions in 2026.

Financial highlights

• Cash and cash equivalents stood at $7.3 million as of December 31, 2025.

• Q4 2025 consolidated net loss was $2.2 million ($0.69 per share), down from $6.7 million ($2.15 per share) in Q4 2024, mainly due to lower impairment, R&D, and tax expenses.

• FY 2025 consolidated net loss was $10.4 million ($3.27 per share), improved from $15.3 million ($5.93 per share) in FY 2024, driven by reduced impairment and R&D costs.

• Q4 2025 revenue was $1.8 million, down from $3.3 million in Q4 2024, primarily due to lower pharmaceutical and active ingredient sales.

• FY 2025 revenue was $7.5 million, down from $9.6 million in FY 2024, mainly due to decreased sales of active ingredients and pharmaceutical revenue.

Outlook and guidance

• Plans to continue cost-saving initiatives and target profitability in 2026.

• Evaluating opportunities for shareholder value enhancement through organic growth and strategic transactions.